Clinical indications for analysis of Alzheimer's disease CSF biomarkers

Revue Neurologique

Volumn 169, Issue 10, 2013, Pages 709-714

  Engelborghs, S ^a  

^a UNIVERSITY OF ANTWERP   (Belgium)

Author keywords

Alzheimer's disease; Amyloid; Biomarkers; Cerebrospinal fluid; Dementia; Mild cognitive impairment; Phospho tau; Tau

Indexed keywords

BETA AMYLOID PROTEIN 1 40; BETA AMYLOID PROTEIN 1 42; BIOLOGICAL MARKER; HYPERPHOSPHORYLATED TAU PROTEIN; TAU PROTEIN; UNCLASSIFIED DRUG;

AGING; ALZHEIMER DISEASE; CLINICAL PRACTICE; CONCENTRATION (PARAMETERS); CONFERENCE PAPER; CONTROLLED STUDY; DEPRESSION; DIAGNOSIS; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; DIAGNOSTIC VALUE; DIFFERENTIAL DIAGNOSIS; HUMAN; MENTAL PATIENT; MULTIINFARCT DEMENTIA; PATHOPHYSIOLOGY; PRODROMAL SYMPTOM; PROTEIN CEREBROSPINAL FLUID LEVEL; RESEARCH DIAGNOSTIC CRITERIA; SENSITIVITY AND SPECIFICITY; WORK;

ALZHEIMER'S DISEASE; AMYLOID; AMYLOÏDE; BIOMARKERS; CEREBROSPINAL FLUID; DEMENTIA; DÉMENCE; LIQUIDE CÉPHALO-RACHIDIEN; MALADIE D'ALZHEIMER; MARQUEURS BIOLOGIQUES; MILD COGNITIVE IMPAIRMENT; PHOSPHO-TAU; TAU; TROUBLES COGNITIFS LÉGERS;

ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; BIOLOGICAL MARKERS; DEMENTIA; DIAGNOSIS, DIFFERENTIAL; HUMANS; TAU PROTEINS;

EID: 84884983255     PISSN: 00353787     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neurol.2013.07.024     Document Type: Conference Paper

References (51)

1. Alzheimer's Association, W. Thies, and L. Bleiler 2011 Alzheimer's disease facts and figures Alzheimers Dement 7 2 2011 208 244 10.1016/j.jalz.2011.02.004 PubMed PMID: 21414557
2. Alzheimer's Disease International The global prevalence of dementia M. Prince, J. Jackson, World Alzheimer Report 2009 2009 Alzheimer's Disease International London, UK 25 46
3. N. Andreasen, L. Minthon, P. Davidsson, E. Vanmechelen, H. Vanderstichele, and B. Winblad Evaluation of CSF-tau and CSF-Abeta42 as diagnostic markers for Alzheimer disease in clinical practice Arch Neurol 58 2001 373 379 (Pubitemid 32217453)
4. T. Arai, I.R. Mackenzie, M. Hasegawa, T. Nonoka, K. Niizato, and K. Tsuchiya Phosphorylated TDP-43 in Alzheimer's disease and dementia with Lewy bodies Acta Neuropathol 117 2009 125 136
5. C. Ballard, I. Ziabreva, R. Perry, J.P. Larsen, J. O'brien, and I. McKeith Differences in neuropathologic characteristics across the Lewy body dementia spectrum Neurology 67 2006 1931 1934 (Pubitemid 44967366)
6. K. Blennow, and H. Hampel CSF markers for incipient Alzheimer's disease Lancet Neurol 2 2003 605 613 (Pubitemid 37162569)
7. K. Blennow, A. Johansson, and H. Zetterberg Diagnostic value of 14-3-3beta immunoblot and T-tau/P-tau ratio in clinically suspected Creutzfeldt-Jakob disease Int J Mol Med 16 2005 1147 1149
8. K. Blennow, H. Hampel, M. Weiner, and H. Zetterberg Cerebrospinal fluid and plasma biomarkers in Alzheimer disease Nat Rev Neurol 6 2010 131 144
9. K. Buerger, M. Ewers, T. Pirttila, R. Zinkowski, I. Alafuzoff, and S.J. Teipel CSF phosphorylated tau protein correlates with neocortical neurofibrillary pathology in Alzheimer's disease Brain 129 2006 3035 3041 (Pubitemid 44684523)
10. D. de Jong, R.W. Jansen, B.P. Kremer, and M.M. Verbeek Cerebrospinal fluid amyloid beta42/phosphorylated tau ratio discriminates between Alzheimer's disease and vascular dementia J Gerontol A Biol Sci Med Sci 61 2006 755 758 (Pubitemid 44148364)
11. G. De Meyer, F. Shapiro, H. Vanderstichele, E. Vanmechelen, S. Engelborghs, and P.P. De Deyn Diagnosis-independent Alzheimer disease biomarker signature in cognitively normal elderly people Arch Neurol 67 2010 949 956
12. J. De Reuck, V. Deramecourt, C. Cordonnier, D. Leys, F. Pasquier, and C.A. Maurage Prevalence of small cerebral bleeds in patients with a neurodegenerative dementia: a neuropathological study J Neurol Sci 300 2011 63 66
13. C. Echavarri, M.C. Caballero, A. Aramendia, F. Garcia-Bragado, and T. Tunon Multiprotein deposits in neurodegenerative disorders: our experience in the tissue brain bank of Navarra Anat Rec (Hoboken) 294 2011 1191 1197
14. S. Engelborghs, K. Sleegers, P. Cras, N. Brouwers, S. Serneels, and E. De Leenheir No association of CSF biomarkers with APOEepsilon4, plaque and tangle burden in definite Alzheimer's disease Brain 130 2007 2320 2326 (Pubitemid 47327622)
15. S. Engelborghs, K. De Vreese, T. Van de Casteele, H. Vanderstichele, B. Van Everbroeck, and P. Cras Diagnostic performance of a CSF-biomarker panel in autopsy-confirmed dementia Neurobiol Aging 29 2008 1143 1159 (Pubitemid 351822410)
16. S. Engelborghs, and N. Le Bastard The role of CSF biomarkers in the diagnostic work-up of mixed vascular-degenerative dementia J Neurol Sci 322 2012 197 199
17. A.M. Fagan, C.M. Roe, C. Xiong, M.A. Mintun, J.C. Morris, and D.M. Holtzman Cerebrospinal fluid tau/beta-amyloid(42) ratio as a prediction of cognitive decline in nondemented older adults Arch Neurol 64 2007 343 349 (Pubitemid 46425688)
18. O. Hansson, H. Zetterberg, P. Buchhave, E. Londos, K. Blennow, and L. Minthon Association between CSF biomarkers and incipient Alzheimer's disease in patients with mild cognitive impairment: a follow-up study Lancet Neurol 5 2006 228 234 (Pubitemid 43238346)
19. F. Hulstaert, K. Blennow, A. Ivanoiu, H.C. Schoonderwaldt, M. Riemenschneider, and P.P. De Deyn Improved discrimination of AD patients using beta-amyloid(1-42) and tau levels in CSF Neurology 52 1999 1555 1562 (Pubitemid 29220627)
20. K. Iqbal, M. Flory, S. Khatoon, H. Soininen, T. Pirttila, and M. Lehtovirta Subgroups of Alzheimer's disease based on cerebrospinal fluid molecular markers Ann Neurol 58 2005 748 757 (Pubitemid 41552550)
21. K. Kasuga, T. Tokutake, A. Ishikawa, T. Uchiyama, T. Tokuda, and O. Onodera Differential levels of alpha-synuclein, beta-amyloid42 and tau in CSF between patients with dementia with Lewy bodies and Alzheimer's disease J Neurol Neurosurg Psychiatry 81 2010 608 610
22. D.S. Knopman, S.T. Dekosky, J.L. Cummings, H. Chui, J. Corey-Bloom, and N. Relkin Practice parameter: diagnosis of dementia (an evidence-based review). Report of the quality standards subcommittee of the American Academy of Neurology Neurology 56 2001 1143 1153 (Pubitemid 32405708)
23. K. Koopman, N. Le Bastard, J.J. Martin, G. Nagels, P.P. De Deyn, and S. Engelborghs Improved discrimination of autopsy-confirmed Alzheimer's disease (AD) from non-AD dementias using CSF P-tau181P Neurochem Int 5 2009 214 218
24. L. Koric, O. Felician, and M. Ceccaldi Use of CSF biomarkers in the diagnosis of Alzheimer's disease in clinical practice Rev Neurol (Paris) 167 2011 474 484
25. N. Le Bastard, P.P. De Deyn, and S. Engelborghs Cerebrospinal fluid biomarkers for the differential diagnosis of dementia. Current medical literature Neurology 25 2009 59 68
26. N. Le Bastard, J.J. Martin, E. Vanmechelen, H. Vanderstichele, P.P. De Deyn, and S. Engelborghs Added diagnostic value of CSF biomarkers in differential dementia diagnosis Neurobiol Aging 31 2010 1867 1876
27. W. Maetzler, I. Liepelt, and M. Reimold Cortical PIB binding in Lewy body disease is associated with Alzheimer-like characteristics Neurobiol Dis 34 2009 107 112
28. N. Mattsson, H. Zetterberg, O. Hansson, N. Andreasen, L. Parnetti, and M. Jonsson CSF biomarkers and incipient Alzheimer disease in patients with mild cognitive impairment JAMA 302 2009 385 393
29. G. McKhann, D. Drachman, M. Folstein, R. Katzman, D. Price, and E.M. Stadlan Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of department of health and human services task force on Alzheimer's disease Neurology 34 1984 939 944 (Pubitemid 14076461)
30. A.J. Mitchell, and M. Shiri-Feshki Rate of progression of mild cognitive impairment to dementia - meta-analysis of 41 robust inception cohort studies Acta Psychiatr Scand 119 2009 252 265
31. B. Mollenhauer, V. Cullen, I. Kahn, B. Krastins, T.F. Outeiro, and I. Pepivani Direct quantification of CSF alpha-synuclein by ELISA and first cross-sectional study in patients with neurodegeneration Exp Neurol 213 2008 315 325
32. B. Mollenhauer, J.J. Locascio, W. Schulz-Schaeffer, F. Sixel-Doring, C. Trenkwalder, and M.G. Schlossmacher Alpha-Synuclein and tau concentrations in cerebrospinal fluid of patients presenting with parkinsonism: a cohort study Lancet Neurol 10 2011 230 240
33. M. Noguchi-Shinohara, T. Tokuda, M. Yoshita, T. Kasai, K. Ono, and M. Nakagawa CSF alpha-synuclein levels in dementia with Lewy bodies and Alzheimer's disease Brain Res 1251 2009 1 6
34. A. Olsson, H. Vanderstichele, N. Andreasen, M.G. De, A. Wallin, and B. Holmberg Simultaneous measurement of beta-amyloid (1-42), total tau, and phosphorylated tau (Thr181) in cerebrospinal fluid by the xMAP technology Clin Chem 51 2005 336 345 (Pubitemid 40175803)
35. L. Parnetti, D. Chiasserini, G. Bellomo, D. Giannandrea, C. De Carlo, and M.M. Qureshi Cerebrospinal fluid Tau/alpha-synuclein ratio in Parkinson's disease and degenerative dementias Mov Disord 26 2011 1428 1435
36. J.L. Price, D.W. McKeel Jr., V.D. Buckles, C.M. Roe, C. Xiong, and M. Grundman Neuropathology of nondemented aging: presumptive evidence for preclinical Alzheimer disease Neurobiol Aging 30 2009 1026 1036
37. F.E. Reesink, A.W. Lemstra, K.D. van Dijk, H.W. Berendse, W.D. van de Berg, and M. Klein CSF alpha-synuclein does not discriminate dementia with Lewy bodies from Alzheimer's disease J Alzheimers Dis 22 2010 87 95
38. N.S. Schoonenboom, Y.A. Pijnenburg, C. Mulder, S.M. Rosso, E.J. Van Elk, and G.J. Van Kamp Amyloid beta(1-42) and phosphorylated tau in CSF as markers for early-onset Alzheimer disease Neurology 62 2004 1580 1584 (Pubitemid 38608199)
39. N.S. Schoonenboom, F.E. Reesink, N.A. Verwey, M.I. Kester, C.E. Teunissen, and P.M. van de Ven Cerebrospinal fluid markers for differential dementia diagnosis in a large memory clinic cohort Neurology 78 2012 47 54
40. M. Shoji, E. Matsubara, M. Kanai, M. Watanabe, T. Nakamura, and Y. Tomidokoro Combination assay of CSF tau, A beta 1-40 and A beta 1-42(43) as a biochemical marker of Alzheimer's disease J Neurol Sci 158 2 1998 134 140 (Pubitemid 28342076)
41. S. Slaets, N. Le Bastard, J.J. Martin, K. Sleegers, C. Van Broeckhoven, and P.P. De Deyn CSF Aβ1-40 improves differential dementia diagnosis in patients with intermediate P-tau181P levels J Alzheimers Dis 36 4 2013 759 767
42. P.E. Spies, D. Slats, J.M. Sjogren, B.P. Kremer, F.R. Verhey, and M.G. Rikkert The cerebrospinal fluid amyloid beta42/40 ratio in the differentiation of Alzheimer's disease from non-Alzheimer's dementia Curr Alzheimer Res 7 2010 470 476
43. D. Strozyk, K. Blennow, L.R. White, and L.J. Launer CSF Abeta 42 levels correlate with amyloid-neuropathology in a population-based autopsy study Neurology 60 2003 652 656 (Pubitemid 36246085)
44. T. Sunderland, G. Linker, N. Mirza, K.T. Putnam, D.L. Friedman, and L.H. Kimmel Decreased beta-amyloid1-42 and increased tau levels in cerebrospinal fluid of patients with Alzheimer disease JAMA 289 2003 2094 2103 (Pubitemid 37430211)
45. T. Tapiola, M. Overmyer, M. Lehtovirta, S. Helisalmi, J. Ramberg, and I. Alafuzoff The level of cerebrospinal fluid tau correlates with neurofibrillary tangles in Alzheimer's disease Neuroreport 8 1997 3961 3963 (Pubitemid 28027217)
46. F. Tateno, R. Sakakibara, T. Kawai, M. Kishi, and T. Murano Alpha-synuclein in the cerebrospinal fluid differentiates synucleinopathies (Parkinson Disease, dementia with Lewy bodies, multiple system atrophy) from Alzheimer disease Alzheimer Dis Assoc Disord 26 3 2012 213 216
47. The Ronald and Nancy Reagan Research Institute of the Alzheimer's Association and the National Institute on Aging Working Group Consensus report of the Working Group on: "Molecular and biochemical markers of Alzheimer's disease" Neurobiol Aging 19 1998 109 116
48. A.E. van der Vlies, N.A. Verwey, F.H. Bouwman, M.A. Blankenstein, M. Klein, and P. Scheltens CSF biomarkers in relationship to cognitive profiles in Alzheimer disease Neurology 72 2009 1056 1061
49. H. Vanderstichele, G. De Meyer, F. Shapiro, S. Engelborghs, P.P. De Deyn, and L.M. Shaw Alzheimer's disease biomarkers: from concept to clinical utility D. Galimberti, E. Scarpini, Biomarkers for early diagnosis of Alzheimer's Disease 2008 Nova Science Publishers, Inc 81 122
50. P.J. Visser, F. Verhey, D.L. Knol, P. Scheltens, L.O. Wahlund, and Y. Freund-Levi Prevalence and prognostic value of CSF markers of Alzheimer's disease pathology in patients with subjective cognitive impairment or mild cognitive impairment in the DESCRIPA study: a prospective cohort study Lancet Neurol 8 2009 619 627
51. J. Wiltfang, H. Esselmann, M. Bibl, M. Hull, H. Hampel, and H. Kessler Amyloid beta peptide ratio 42/40 but not A beta 42 correlates with phospho-Tau in patients with low- and high-CSF A beta 40 load J Neurochem 101 2007 1053 1059 (Pubitemid 46683864)